

ARCA biopharma, Inc.
Form 8-K
March 25, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): March 25, 2013 (March 21, 2013)

ARCA biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Edgar Filing: ARCA biopharma, Inc. - Form 8-K

(State or Other Jurisdiction
of Incorporation)

(Commission

(I.R.S. Employer

File Number)

Identification No.)

8001 Arista Place, Suite 430, Broomfield, CO 80021

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 3 Securities and Trading Markets

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 21, 2013, The Nasdaq Stock Market (NASDAQ), notified ARCA biopharma, Inc. (ARCA or the Company) that the Company has regained compliance with the applicable minimum bid price rule of The NASDAQ Capital Market, and is in compliance with all other applicable requirements required for listing on The NASDAQ Capital Market. Accordingly, the NASDAQ Listing Qualifications Panel (the Panel) has determined to continue the listing of ARCA s securities on The NASDAQ Stock Market (Symbol: ABIO).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 25, 2013

ARCA biopharma, Inc.

(Registrant)

By: /s/ Patrick M. Wheeler

Name: Patrick M. Wheeler

Title: Chief Financial Officer